Beth Anderson
Michigan Department of Community Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Beth Anderson.
Journal of Cancer Epidemiology | 2012
Beth Anderson; Jennifer McLosky; Elizabeth Wasilevich; Sarah Lyon-Callo; Debra Duquette; Glenn Copeland
Introduction. Women diagnosed with breast cancer at a young age are more likely to carry a cancer predisposing genetic mutation. Per the current NCCN recommendations, women diagnosed under age 50 should be referred to cancer genetic counseling for further risk evaluation. This study seeks to assess patient-reported barriers and facilitators to receiving genetic counseling and risk assessment among a community-based population of young breast cancer survivors (YBCS). Methods. Through the Michigan Cancer Surveillance Program, a state-based cancer registry, 488 women diagnosed with breast cancer before age 50 in 2006-2007 were identified. They received a mail survey regarding family history and facilitators and barriers to receiving genetic counseling and risk assessment. Results. Responses were received from 289 women (59.2%). One hundred twenty-two (42.2%) reported having received cancer genetic counseling. The most frequent reason identified for receiving services was to benefit their familys future. The top reasons for not attending were “no one recommended it” and “medical insurance coverage issues.” Discussion. This study is the first published report using a state cancer registry to determine facilitators and barriers to receiving genetic counseling and risk assessment among YBCS. These findings demonstrate the need for additional awareness and education about appropriate indications for genetic services.
Genetics in Medicine | 2012
Debra Duquette; Amy Zlot; Joan Foland; Beth Anderson; Rebecca Giles; Jennifer Wrathall; Muin J. Khoury
Purpose:Direct-to-consumer personal genomic tests are widely available, but population-based data are limited on awareness and use of these tests among the general public in the United States.Methods:We assessed awareness and use of direct-to-consumer personal genomic tests in Connecticut, Michigan, Oregon, and Utah using the 2009 Behavioral Risk Factor Surveillance System and compared the state results to the 2008 national HealthStyles survey results.Results:Awareness was the highest in Oregon (29.1%) and the lowest in Michigan (15.8%). Factors associated with awareness across all states and nationally were higher education, higher income, and increasing age, except among those 75 years or older. Less than 1% of respondents had used the tests, with about one-half to three-quarters of those sharing the results with a health-care provider.Conclusions:Awareness of direct-to-consumer genetic tests is greater in this study as compared with a related study conducted in 2006, whereas use is similarly low in both studies. The few respondents who reported using the tests often reported sharing their results with their health-care provider, indicating an important opportunity for health-care providers to offer patient education regarding these tests. Public health agencies have important roles in surveillance, education, and policy development on direct-to-consumer genomic tests.Genet Med 2012:14(10):860–867
Stroke | 2009
Beth Anderson; Ann P. Rafferty; Sarah Lyon-Callo; Chris Fussman; Mathew J. Reeves
Background and Purpose— Although tissue plasminogen activator (tPA) is an effective therapy for acute ischemic stroke, treatment rates remain low. Efforts to address the underuse of tPA include public education to increase the recognition of stroke symptoms and the awareness of tPA treatment. Our objective was to determine the level of knowledge about tPA treatment for acute stroke among a representative sample of Michigan adults. Methods— The Michigan Behavioral Risk Factor Survey (BRFS) is a random-digit-dial telephone survey of adults conducted annually as part of the national BRFS. Questions regarding tPA treatment for acute stroke were included in the 2004 Michigan BRFS. We examined the prevalence of awareness using &khgr;2 tests and generated multivariable logistic regression models. Results— Among 4724 respondents, only 32.2% (95% CI=30.8 to 33.8%) were aware of the existence of tPA treatment for acute stroke, of whom 52.7% (50.0 to 55.4%) knew that it needed to be administered within 3 hours of symptom onset. Awareness of tPA was higher among middle aged adults, females, whites, and those with higher education and income. Awareness of the time window for tPA was higher among middle aged adults and whites. Conclusions— In this population-based survey only a third of the public were aware of tPA as a treatment for stroke, and only 1 in 6 were aware that the treatment exists and needs to be given within 3 hours of symptom onset. Continuing efforts are necessary to increase public knowledge about tPA treatment for acute stroke.
Cancer Causes & Control | 2017
Maria C. Katapodi; Deb Duquette; James J. Yang; Kari Mendelsohn-Victor; Beth Anderson; Christos Nikolaidis; Emily Mancewicz; Laurel Northouse; Sonia A. Duffy; David L. Ronis; Kara J. Milliron; Nicole Probst-Herbst; Sofia D. Merajver; Nancy K. Janz; Glenn Copeland; Scott Roberts
PurposeCancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors—YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives.MethodsA random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS’ willingness to contact at-risk relatives.ResultsThe 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at-risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at-risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS.ConclusionIt is feasible to recruit diverse families at risk for hereditary cancer from a population-based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large-scale public health genomic initiatives in the era of precision medicine.
Preventing Chronic Disease | 2011
Beth Anderson; Sarah Lyon-Callo; Christopher Fussman; Gwendoline Imes; Ann P. Rafferty
Journal of Genetic Counseling | 2015
Alicia A. Parkman; Joan Foland; Beth Anderson; Debra Duquette; Holly Sobotka; Mary Lynn; Shelley Nottingham; William David Dotson; Summer L. Cox
BMC Cancer | 2013
Maria C. Katapodi; Laurel Northouse; Ann Schafenacker; Debra Duquette; Sonia A. Duffy; David L. Ronis; Beth Anderson; Nancy K. Janz; Jennifer McLosky; Kara J. Milliron; Sofia D. Merajver; Linh M. Duong; Glenn Copeland
Ethnicity & Disease | 2009
Chris Fussman; Ann P. Rafferty; Mathew J. Reeves; Shannon Zackery; Sarah Lyon-Callo; Beth Anderson
Preventing Chronic Disease | 2011
Beth Anderson; Sarah Lyon-Callo; Christopher Fussman; Gwendoline Imes; Ann P. Rafferty
Breast Cancer Research and Treatment | 2018
Tarsha Jones; Debra Duquette; Meghan Underhill; Chang Ming; Kari Mendelsohn-Victor; Beth Anderson; Kara J. Milliron; Glenn Copeland; Nancy K. Janz; Laurel Northouse; Sonia M. Duffy; Sofia D. Merajver; Maria C. Katapodi